Alvotech and Stada are back on track with a fresh marketing license deal for the former’s biosimilar rival to Amgen’s denosumab brands Prolia and Xgeva, despite previously terminating their licensing and supply partnership for three of Alvotech’s biosimilars, including denosumab.
Alvotech And Stada Are Back With A Denosumab Biosimilar Deal
The Duo Initially Started Their Biosimilar Partnership In 2019
With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.
